Navigation Links
MS drug development agreement based on WEHI's medicinal chemistry
Date:7/2/2008

Research conducted at The Walter and Eliza Hall Institute (WEHI) has contributed significantly to a major licensing agreement signed between Australian biotechnology company, Bionomics, (ASX:BNO) and Germany-based pharmaceutical company, Merck Serono.

Under the Development and Licensing Agreement, Merck Serono will seek to develop new treatments for multiple sclerosis (MS) and other autoimmune conditions. These prospective treatments will be based upon compounds from Bionomics' Kv1.3 program, which WEHI had a fundamental role in developing.

The Kv1.3 program has its origins in the late 1990s, when WEHI's Dr Jonathan Baell and collaborators discovered that certain derivatives of a natural product called khellinone could block a potassium channel called Kv1.3. This potassium channel selectively inhibits autoreactive T cells, such as those that attack the myelin sheath in people with MS.

Dr Baell says, "Our research in this area had a rocky start, but when our first patents were published in 2003, Start-Up Australia approached us with an interest in licensing the intellectual property. This came to fruition in late 2004 through their investee company, Iliad, which was able to resource the medicinal chemistry effort required."

In 2005, Iliad was acquired by Bionomics, which further accelerated progress with the program.

Dr Baell continues, "There was a great meeting of minds between chemists from WEHI and Bionomics, leading to a significant expansion of the patent portfolio. Bionomics also established an in-house biology platform that effectively serviced the whole program."

"During the whole process, every scientist at WEHI and Bionomics maintained a focus upon what we were trying to achieve: a treatment for MS, a debilitating disease that is tragically common among young adults. Our progress and achievements to date demonstrate that with intense tenacity and a collaborative approach, academic drug discovery programs can produce great outcomes."


'/>"/>

Contact: Brad Allan
allan@wehi.EDU.AU
61-393-452-345
Research Australia
Source:Eurekalert

Related medicine news :

1. Ikaria(R) Strengthens Research & Development Team
2. Justice Department Reaches Settlement to Improve Conditions at a Nebraska Developmental Center
3. Contract Research Development Debuts at MD&M Touting Expertise, Innovation and Collaboration
4. The "DNDi Project of the Year": The Development of Fexinidazole to Treat "Sleeping Sickness"
5. Oaks Development Group Closes on Second San Antonio Project
6. Avalon Pharmaceuticals names lead development candidate in beta-catenin inhibitor program
7. Crucial factors in lymphoma development and survival discovered
8. World research leaders gather in Finland to accelerate the development of bioactive paper
9. Healthation CEO Appoints New Senior Vice President of Business Development
10. Penn researchers find key developmental pathway activates lung stem cells
11. Verus Pharmaceuticals Announces Divestiture of Pediatric GI Development Program to Meritage Pharma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/7/2016)... ... 2016 , ... Dr. Todd Hobgood , certificated in ... surgical expertise. Technically known as deoxycholic acid or previously as ATX-101, Kybella® ... for reduction of fat below the chin (aka the “double chin”). Medication side ...
(Date:2/6/2016)... ... , ... With the FCPX LUT: Summer pack from Pixel Film ... LUT is a Lookup Table that contains a mathematical formula for modifying an image. ... By manipulating each pixel, LUT's can change each color range differently, it gives the ...
(Date:2/5/2016)... ... February 05, 2016 , ... Steven Tonkinson, 36, of ... completed every year since it started in 2003. This year, he ran all 26.2 ... fellow runners and NBA team the Miami Heat. , This Sunday, while many are ...
(Date:2/5/2016)... ... February 05, 2016 , ... Today, the Whole-Food Warrior TV show, hosted ... feature with author Jahnavi Foster, specialist in healthy vegetarian cuisine, will stream on Friday, ... on his weekly Whole-Food Warrior TV show, Frank Davis highlights Whole-Food Warriors - people ...
(Date:2/5/2016)... ... February 05, 2016 , ... The Muscular Dystrophy ... Kitchen restaurants, launched the 14th annual “Appetite for a Cure” campaign on Feb. ... dystrophy, ALS and related diseases that severely limit strength and mobility. , ...
Breaking Medicine News(10 mins):
(Date:2/4/2016)... --  Bernstein Liebhard LLP today announced that a securities ... Court for the District of Arizona ... persons or entities who purchased common shares of Insys Therapeutics ... March 3, 2015 through January 25, 2016 (the "Class Period").  ... violations of the Securities Exchange Act of 1934.  ...
(Date:2/4/2016)... 4, 2016  Montoya Love is recognized by Continental ... of Pharmaceuticals. Montoya is the Regulatory Systems Operations Manager ... Manufacturing and selling a broad ... provides healthcare institutions, clinical laboratories and life science ... across the globe. ...
(Date:2/4/2016)... , Feb. 4, 2016 Frontier Pharma: ... Commercializing First-in-Class Innovation Chronic Obstructive ... with chronic inflammation of the airways and lungs. ... symptoms make the disease one of the leading ... death in the world. COPD is linked to ...
Breaking Medicine Technology: